Clinical trials: Resistant Major Depressive Disorder
Treatment Resistant Depression
Deep Brain Stimulation in Treatment Resistant Depression
Recurrent major depressive disorder affects about 3-5% of the population. It is anticipated that by 2020, depression will be the most common cause of disability worldwide in the 18-55 age group.
- Trial name
- NCT01435148
- Testing
- Deep Brain Stimulation, implanted
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- North Bristol NHS Trust
Major Depressive Disorder, Major Depressive Disorder w/ Psychotic Features
Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features
Studies have shown that people with certain disorders have an increased risk of developing a condition called Metabolic Syndrome (MS).
- Conditions
- Major Depressive Disorder, Major Depressive Disorder w/ Psychotic Features, Metabolic Syndrome
- Trial name
- NCT01310140
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Massachusetts General Hospital
Resistant Major Depression
Pentoxifylline for Treatment of Resistant Major Depression
A growing body of evidence has highlighted the role of inflammation and phosphodiesterases (PDE)-related pathways in the pathogenesis of neuropsychiatric illnesses such as depression/mood disorders.
- Trial name
- NCT05324735
- Testing
- Pentoxifylline
- Where
- Iraq
- Volunteers
- 60 people
- Sponsor
- Hawler Medical University
Depression
Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
The purpose of this study it to evaluate the long-term safety and tolerability of BMS-820836 in patients with depression.
- Trial name
- NCT01361555
- Testing
- BMS-820836
- Where
- 144 sites in United States, Argentina and 10 more
- Volunteers
- 789 people
- Sponsor
- Bristol-Myers Squibb
Major Depression
Epidural Stimulation for Resistant Depression Treatment
This study aims to analyze the effectiveness and feasibility of using an implantable system that provides epidural electrical stimulation directly to the left prefrontal dorsolateral cortex (Brodmann area 9/46) in patients with…
- Trial name
- NCT02622633
- Testing
- Epidural Electrode
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- University of Brasilia
Major Depressive Disorder
RESISTance Exercise for Depression Trial
Depression is a leading cause of disability worldwide and current treatments are ineffective for many people. This trial will investigate the efficacy of a 16-week high vs low dose resistance exercise training program for the…
- Trial name
- RESIST (NCT06110897)
- Testing
- High Dose Resistance Exercise Training, Low Dose Resistance Exercise Training Group
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- University of Wisconsin, Madison
Depression
Effectiveness of Pramipexole for Treatment-Resistant Depression
This study will evaluate the effectiveness of pramipexole (Mirapex) in managing treatment-resistant depression.
- Trial name
- NCT00231959
- Testing
- Pramipexole (Mirapex)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Treatment-resistant Depression (TRD), Major Depression
Relationship of Peripheral Inflammatory and Neuroprotective Biomarkers With Response to Intermittent Theta Burst Stimulation in Treatment-Resistant Depression
Treatment-resistant depression (TRD) is a major clinical challenge affecting a substantial proportion of patients with major depressive disorder who do not adequately respond to conventional antidepressant treatments.
- Trial name
- TRD-BIOTMS (NCT07673913)
- Testing
- Intermittent Theta Burst Stimulation (iTBS)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Treatment-Resistant Depression
Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder
This is an ancillary study to a clinical trial that is being conducted at Massachusetts General Hospital. Investigators at MGH are conducting a clinical trial to test the efficacy of ziprasidone together with escitalopram for…
- Trial name
- NCT01598324
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mclean Hospital
Adrenal Gland Hyperfunction, Cardiovascular Disease
Heart Disease Risk Factors in Major Depression
A series of studies in patients with major depression have consistently demonstrated a doubling of the mortality rate at any age, independent of suicide.
- Conditions
- Adrenal Gland Hyperfunction, Cardiovascular Disease, Involutional Depression
- Trial name
- NCT00001969
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
- Trial name
- NCT01234558
- Testing
- GLYX-13
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Major Depressive Disorder
Antidepressant Incomplete Response Depression
Observational, non-interventional, longitudinal, prospective,multicenter, open label (No treatment is involved). 3 assessment will be carried out .
- Trial name
- DRIA (NCT00782964)
- Where
- 48 sites in Spain
- Volunteers
- 364 people
- Sponsor
- AstraZeneca
Depression, Bipolar Depression
Efficacy of Convulsive Therapies During Continuation
This trial aims to assess the efficacy and tolerability of Magnetic Seizure Therapy (MST) and two different forms of electroconvulsive therapy (ECT) in sustaining response during and after a course of continuation treatment.
- Conditions
- Depression, Bipolar Depression, Unipolar Depression, Treatment Resistant Depression
- Trial name
- CORRECT-C (NCT03711019)
- Testing
- Magnetic Seizure Therapy (MST), RUL-UB ECT, Bitemporal ECT
- Where
- 3 sites in Canada
- Volunteers
- 106 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment Resistant Depression, Major Depressive Disorder
Biomarker-guided rTMS for Treatment Resistant Depression
Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. The investigators are continuing to learn how to optimize outcomes from rTMS treatment.
- Trial name
- BioTMS (NCT04041479)
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- 2 sites in United States
- Volunteers
- 348 people
- Sponsor
- Weill Medical College of Cornell University
Major Depressive Disorder
Randomized Controlled Trial of Conventional vs Theta Burst rTMS
This trial will compare a novel form of rTMS, intermittent Theta Burst Stimulation to the standard conventional high frequency left sided stimulation protocol.
- Trial name
- HFL vs TBS (NCT01887782)
- Testing
- HFL rTMS, iTBS
- Where
- 3 sites in Canada
- Volunteers
- 414 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder (MDD)
The Effect of Transcranial Magnetic Stimulation Treatment on Microvasculature Stracture of the Retina and the Choroid
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option in treatment-resistant depression.
- Trial name
- TMS_OCT-A (NCT06708013)
- Testing
- Transcranial Magnetic Stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Treatment Resistant Depression
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression: OL Cohort
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- SAINT-TRD (NCT03240692)
- Testing
- Accelerated theta-burst stimulation treatment
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Stanford University
Depression, Major Depressive Disorder
Reward Emotion Learning and Ketamine Study
Ketamine's efficacy as an antidepressant is now well established yet the mechanisms underlying its antidepressant effect are yet to be fully described.
- Conditions
- Depression, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- RELAKS (NCT04850911)
- Testing
- Ketamine Hydrochloride
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Treatment Resistant Depression
Berlin Deep Brain Stimulation Depression Study
In this study efficacy and safety of deep brain stimulation of the cingulate cortex in 20 patients with treatment resistant major depression will be investigated.
- Trial name
- BDDS (NCT00531726)
- Testing
- DBS of Cg25
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- Charite University, Berlin, Germany
Major Depressive Disorder, Treatment Resistant Depression
Investigation of the Effects of Repetitive Transcranial Magnetic Stimulation on Cognition in Depression
According to the World Health Organization, MDD is attributed as the leading cause of disability worldwide, leaving 300 million individuals affected.
- Trial name
- NCT03977038
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre